Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics develops treatments for rare diseases, starting with a drug candidate for Friedreich's ataxia that uses its cell penetrating peptide platform. It last closed at $2.99 on Nov 17, down 0.33% on the day. The average 12-month price target from 2 analysts is $11.00 (+267.9% from the last close), with a high of $13.00 and a low of $9.00. In the past 30 days there were 3 dark pool prints totaling $382K, the largest $143K.
Key Stats
Last 12 monthsNot reported for this period.
From LRMR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on LRMR in the past 90 days. The average target is $11.00, with a high of $13.00 and a low of $9.00, compared with the last close of $2.99.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 17 | Wedbush | Maintained | Buy | $9 |
| Sep 14 | Leerink Partners | Assumed coverage | Buy | $13 |
| Jul 2 | HC Wainwright & Co. | Assumed coverage | Buy | $10 |
| Jun 30 | Baird | Maintained | Buy | $5 |
| May 27 | JP Morgan | Initiated | Buy | $9 |
Technical Analysis
The stock is 14% above its 20 day and 3% above its 50 day average. It is 26% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 59). The nearest support is the swing low (Jun 29) at $2.92, and the nearest resistance the Pivot at $3.01.
| RSI (14) | 58.61 | Middle of its range | Neutral |
| MACD | 0.04 | Above its signal line | Bullish |
| Stochastic | 78.7 | Middle of its range | Neutral |
| ADX (14) | 23.1 | Weak trend | |
| Williams %R | -29.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 157.7 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +17.7% | Change over 10 sessions | Bullish |
| ATR (14) | $0.26 | Typical daily range, 8.5% of price |
| RSI (14) | 45.81 | Middle of its range | Neutral |
| MACD | -0.34 | Below its signal line | Bearish |
| Stochastic | 34.8 | Middle of its range | Neutral |
| ADX (14) | 18.2 | No clear trend | |
| Williams %R | -57.2 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -38.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −23.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.57 | Typical daily range, 18.9% of price |
What happened before
See how LRMR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How LRMR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
Whale Options Flow
90DNo whale options trades in LRMR in the last 90 days.
Dark Pool
30DLRMR Institutional Ownership
Full report →- ▼59 buying vs 86 selling
- ▲Held by funds +8.4 pts
- ▼Funds holding -17
- ▼Superinvestors: 1 added, 3 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 146 | 163 | −10.4% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | 99.6% | 91.2% | +8.4 pts |
| New / increased | 12 / 47 | 32 / 68 | −41.0% |
| Reduced / sold out | 56 / 30 | 41 / 30 | +21.1% |
| Put/call ratio | – | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LRMR is in one of them and how their past LRMR trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LRMR in an article yet. Here's the latest on the wider market.
About Larimar Therapeutics
Larimar Therapeutics is a biotechnology company based in Bala Cynwyd, Pennsylvania, that develops treatments for complex rare diseases. Its lead candidate, nomlabofusp, is a drug given by injection under the skin that is designed to deliver frataxin, a protein the body needs, to patients with Friedreich's ataxia. The company uses its cell penetrating peptide platform, which helps therapeutic molecules cross cell membranes, and it aims to apply that platform to other rare diseases. The drug is still in clinical development and is not yet approved for sale.
- Headquarters
- Bala Cynwyd, PA
- Founded
- 2005
- Website
- zafgen.com ↗



